Scoliosis: Sainte-Justine Research Center
MONTREAL, Nov. 18 /CNW Telbec/ - The CHU Sainte-Justine Research Center is proud to inaugurate its state-of-the art laboratory dedicated to the molecular genetics of musculoskeletal disorders. The laboratory with its global infrastructure is like no other in the world. Its aims will be twofold: to develop innovative diagnostic tools and therapeutic treatments to prevent and stop disease progression through tailored pharmacotherapies.
Dr. Alain Moreau runs the Laboratory whose mission is to develop new molecular diagnostic tools for the early screening of scoliosis and other disorders that affect large numbers of children and adults and for which there are no tests. In addition, this state-of-the-art infrastructure will enable Dr. Moreau and his team to develop novel therapeutics aimed at preventing scoliosis or stopping its progression at an early stage. This represents a remarkable breakthrough leading to customized medicine that will revolutionize the treatment of scoliosis as well as other diseases such as osteoarthritis and osteoporosis. With all these advances, Dr. Moreau considers that "we are now, for the first time, in the exceptional position of being able to foresee the eradication of the disease in the very near future with the development of the first drugs within ten years' time."
Dr. Guy A. Rouleau, Director of the CHU Sainte-Justine Research Center, states that "Dr. Moreau's research work will lead to significant advances in the field of musculoskeletal disorders by preparing today for the medicine of tomorrow. In fact, his activities in the field of genomics are going to lead to a type of medicine that is adapted to a patient's genetic profile in order to deliver a targeted therapeutic response tailored to an individual's health problems."
Scoliosis: Saint Justine Research Center - follow the story
Dr. Alain Moreau runs the Laboratory whose mission is to develop new molecular diagnostic tools for the early screening of scoliosis and other disorders that affect large numbers of children and adults and for which there are no tests. In addition, this state-of-the-art infrastructure will enable Dr. Moreau and his team to develop novel therapeutics aimed at preventing scoliosis or stopping its progression at an early stage. This represents a remarkable breakthrough leading to customized medicine that will revolutionize the treatment of scoliosis as well as other diseases such as osteoarthritis and osteoporosis. With all these advances, Dr. Moreau considers that "we are now, for the first time, in the exceptional position of being able to foresee the eradication of the disease in the very near future with the development of the first drugs within ten years' time."
Dr. Guy A. Rouleau, Director of the CHU Sainte-Justine Research Center, states that "Dr. Moreau's research work will lead to significant advances in the field of musculoskeletal disorders by preparing today for the medicine of tomorrow. In fact, his activities in the field of genomics are going to lead to a type of medicine that is adapted to a patient's genetic profile in order to deliver a targeted therapeutic response tailored to an individual's health problems."
Scoliosis: Saint Justine Research Center - follow the story
Comments